2iul: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Human angiotensin-converting enzyme is an important drug target for which | Human angiotensin-converting enzyme is an important drug target for which little structural information has been available until recent years. The slow progress in obtaining a crystal structure was due to the problem of surface glycosylation, a difficulty that has thus far been overcome by the use of a glucosidase-1 inhibitor in the tissue culture medium. However, the prohibitive cost of these inhibitors and incomplete glucosidase inhibition makes alternative routes to minimizing the N-glycan heterogeneity desirable. Here, glycosylation in the testis isoform (tACE) has been reduced by Asn-Gln point mutations at N-glycosylation sites, and the crystal structures of mutants having two and four intact sites have been solved to 2.0 A and 2.8 A, respectively. Both mutants show close structural identity with the wild-type. A hinge mechanism is proposed for substrate entry into the active cleft, based on homology to human ACE2 at the levels of sequence and flexibility. This is supported by normal-mode analysis that reveals intrinsic flexibility about the active site of tACE. Subdomain II, containing bound chloride and zinc ions, is found to have greater stability than subdomain I in the structures of three ACE homologues. Crystallizable glycosylation mutants open up new possibilities for cocrystallization studies to aid the design of novel ACE inhibitors. | ||
==Disease== | ==Disease== | ||
| Line 16: | Line 16: | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Acharya, K | [[Category: Acharya, K R.]] | ||
[[Category: Corradi, H | [[Category: Corradi, H R.]] | ||
[[Category: Natesh, R.]] | [[Category: Natesh, R.]] | ||
[[Category: Sewell, B | [[Category: Sewell, B T.]] | ||
[[Category: Sturrock, E | [[Category: Sturrock, E D.]] | ||
[[Category: Watermeyer, J | [[Category: Watermeyer, J M.]] | ||
[[Category: ACT]] | [[Category: ACT]] | ||
[[Category: CL]] | [[Category: CL]] | ||
| Line 45: | Line 45: | ||
[[Category: zinc]] | [[Category: zinc]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:56:09 2008'' | ||
Revision as of 18:56, 21 February 2008
|
HUMAN TACE G13 MUTANT
OverviewOverview
Human angiotensin-converting enzyme is an important drug target for which little structural information has been available until recent years. The slow progress in obtaining a crystal structure was due to the problem of surface glycosylation, a difficulty that has thus far been overcome by the use of a glucosidase-1 inhibitor in the tissue culture medium. However, the prohibitive cost of these inhibitors and incomplete glucosidase inhibition makes alternative routes to minimizing the N-glycan heterogeneity desirable. Here, glycosylation in the testis isoform (tACE) has been reduced by Asn-Gln point mutations at N-glycosylation sites, and the crystal structures of mutants having two and four intact sites have been solved to 2.0 A and 2.8 A, respectively. Both mutants show close structural identity with the wild-type. A hinge mechanism is proposed for substrate entry into the active cleft, based on homology to human ACE2 at the levels of sequence and flexibility. This is supported by normal-mode analysis that reveals intrinsic flexibility about the active site of tACE. Subdomain II, containing bound chloride and zinc ions, is found to have greater stability than subdomain I in the structures of three ACE homologues. Crystallizable glycosylation mutants open up new possibilities for cocrystallization studies to aid the design of novel ACE inhibitors.
DiseaseDisease
Known diseases associated with this structure: Alzheimer disease, susceptibility to OMIM:[106180], Angiotensin I-converting enzyme, benign serum increase OMIM:[106180], Diabetic nephropathy, susceptibility to OMIM:[106180], Myocardial infarction, susceptibility to OMIM:[106180], Renal tubular dysgenesis OMIM:[106180], SARS, progression of OMIM:[106180]
About this StructureAbout this Structure
2IUL is a Single protein structure of sequence from Homo sapiens with , , and as ligands. Known structural/functional Site: . Full crystallographic information is available from OCA.
ReferenceReference
Structure of testis ACE glycosylation mutants and evidence for conserved domain movement., Watermeyer JM, Sewell BT, Schwager SL, Natesh R, Corradi HR, Acharya KR, Sturrock ED, Biochemistry. 2006 Oct 24;45(42):12654-63. PMID:17042482
Page seeded by OCA on Thu Feb 21 17:56:09 2008
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Pages with broken file links
- Homo sapiens
- Single protein
- Acharya, K R.
- Corradi, H R.
- Natesh, R.
- Sewell, B T.
- Sturrock, E D.
- Watermeyer, J M.
- ACT
- CL
- NAG
- ZN
- Ac
- Alternative splicing
- Carboxypeptidase
- Chloride
- Glycoprotein
- Glycosidase
- Hydrolase
- Membrane
- Metal-binding
- Metalloprotease
- Mutant
- Peptidyl dipeptidase
- Phosphorylation
- Polymorphism
- Protease
- Transmembrane
- Type-i membrane-anchored protein
- Zinc